Japanese journal of clinical oncology · 2026
Characteristics and reasons for low-dose fentanyl patch use in opioid-naïve versus non-naïve patients with cancer pain.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kajiura Shinya, Chikaoka Shingo, Yagi Yuta, Ryu Nobukazu, Mizuno Yoko, Nakayama Yurika, Ueda Yuko, Motoo Iori, Ando Takayuki, Yasuda Ichiro, Kato Atsushi, Hayashi Ryuji
Аннотация
BACKGROUND: Transdermal fentanyl is usually reserved for opioid-tolerant patients, but in Japan, a low-dose transdermal fentanyl patch (0.5 mg, delivering ~6 μg/h; Fentos tape®) has been approved for opioid-naïve cancer pain. However, real-world data on how this formulation is prescribed are limited. This study aimed to compare patient characteristics and prescribing reasons between opioid-naïve and non-naïve patients and to identify factors associated with opioid-naïve initiation.
METHODS: We retrospectively reviewed 107 patients who were started on a low-dose transdermal fentanyl patch (0.5 mg, delivering ~6 μg/h) at a Japanese university hospital. Patients were classified as opioid-naïve [no prior opioid (n = 36)] or non-naïve [switched (n = 71)]. Data on demographics, cancer type, department, care setting, and reasons for patch use were categorized. Multivariate logistic regression examined factors associated with opioid-naïve initiation.
RESULTS: Opioid-naïve patients more often had gastrointestinal cancer and were managed by gastrointestinal (GI)-related departments. Age and inpatient status were similar between the groups. The distribution of reasons for prescribing did not significantly differ (oral intake difficulty, 39% vs. 42%; bowel problems, 14% vs. 10%; renal dysfunction, 8% vs. 4%). GI cancer (adjusted odds ratio [OR], 4.43; 95% confidence interval [CI], 1.75-11.18) and GI-related department (adjusted OR, 4.57; 95% CI, 1.67-12.53) were independently associated with opioid-naïve initiation.
CONCLUSION: In this cohort, low-dose transdermal fentanyl patches were preferentially used as first-line strong opioids in patients with GI cancers and those under GI specialist care, rather than being limited to those with clear swallowing difficulty.
METHODS: We retrospectively reviewed 107 patients who were started on a low-dose transdermal fentanyl patch (0.5 mg, delivering ~6 μg/h) at a Japanese university hospital. Patients were classified as opioid-naïve [no prior opioid (n = 36)] or non-naïve [switched (n = 71)]. Data on demographics, cancer type, department, care setting, and reasons for patch use were categorized. Multivariate logistic regression examined factors associated with opioid-naïve initiation.
RESULTS: Opioid-naïve patients more often had gastrointestinal cancer and were managed by gastrointestinal (GI)-related departments. Age and inpatient status were similar between the groups. The distribution of reasons for prescribing did not significantly differ (oral intake difficulty, 39% vs. 42%; bowel problems, 14% vs. 10%; renal dysfunction, 8% vs. 4%). GI cancer (adjusted odds ratio [OR], 4.43; 95% confidence interval [CI], 1.75-11.18) and GI-related department (adjusted OR, 4.57; 95% CI, 1.67-12.53) were independently associated with opioid-naïve initiation.
CONCLUSION: In this cohort, low-dose transdermal fentanyl patches were preferentially used as first-line strong opioids in patients with GI cancers and those under GI specialist care, rather than being limited to those with clear swallowing difficulty.